1921
Volume 94, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Poor quality antimalarials, including falsified, substandard, and degraded drugs, are a serious health concern in malaria-endemic countries. Guidelines are lacking on how to distinguish between substandard and degraded drugs. “Forced degradation” in an oven was carried out on three common artemisinin-based combination therapy (ACT) brands to detect products of degradation using liquid chromatography mass spectrometry and help facilitate classification of degraded drugs. “Natural aging” of 2,880 tablets each of ACTs artemether/lumefantrine and artesunate/amodiaquine was undertaken to evaluate their long-term stability in tropical climates. Samples were aged in the presence and absence of light on-site in Ghana and in a stability chamber (London), removed at regular intervals, and analyzed to determine loss of the active pharmaceutical ingredients (APIs) over time and detect products of degradation. Loss of APIs in naturally aged tablets (both in Ghana and the pharmaceutical stability chamber) was 0–7% over 3 years (∼12 months beyond expiry) with low levels of degradation products detected. Using this developed methodology, it was found that a quarter of ACTs purchased in Enugu, Nigeria (concurrent study), that would have been classified as substandard, were in fact degraded. Presence of degradation products together with evidence of insufficient APIs can be used to classify drugs as degraded.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.15-0665
2016-05-04
2017-12-12
Loading full text...

Full text loading...

/deliver/fulltext/14761645/94/5/993.html?itemId=/content/journals/10.4269/ajtmh.15-0665&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2015. Malaria Fact Sheet No. 94. Available at: http://www.who.int/mediacentre/factsheets/fs094/en/. Accessed August 28, 2015.
  2. Mutabingwa TK, , 2005. Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy! Acta Trop 95: 305315.[Crossref]
  3. Milhous WK, Weina PJ, , 2010. The botanical solution for malaria. Science 327: 279280.[Crossref]
  4. O'Neill PM, , 2004. Medicinal chemistry: a worthy adversary for malaria. Nature 430: 838839.[Crossref]
  5. Haynes RK, Krishna S, , 2004. Artemisinins: activities and actions. Microbes Infect 6: 13391346.[Crossref]
  6. Krishna S, Bustamante L, Haynes RK, Staines HM, , 2008. Artemisinins: their growing importance in medicine. Trends Pharmacol Sci 29: 520527.[Crossref]
  7. Kaur H, Goodman C, Thompson E, Thompson K-A, Masanja I, Kachur SP, Abdulla S, , 2008. A nationwide survey of the quality of antimalarials in retail outlets in Tanzania. PLoS One 3: e3403.[Crossref]
  8. Affum AO, Lowor S, Osae SD, Dickson A, Gyan BA, Tulasi D, , 2013. A pilot study on quality of artesunate and amodiaquine tablets used in the fishing community of Tema, Ghana. Malar J 12: 220.[Crossref]
  9. Phanouvong S, Raymond C, Krech L, Dijiba Y, Mam B, Lukulay P, Socheat D, Sovannarith T, Sokhan C, , 2013. The quality of antimalarial medicines in western Cambodia: a case study along the Thai-Cambodian border. Southeast Asian J Trop Med Public Health 44: 349362.
  10. Dondorp AM, Newton PN, Mayxay M, Van Damme W, Smithuis FM, Yeung S, Petit A, Lynam AJ, Johnson A, Hien TT, McGready R, Farrar JJ, Looareesuwan S, Day NPJ, Green MD, White NJ, , 2004. Fake antimalarials in southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 9: 12411246.[Crossref]
  11. Hastings IM, Korenromp EL, Bloland PB, , 2007. The anatomy of a malaria disaster: drug policy choice and mortality in African children. Lancet Infect Dis 7: 739748.[Crossref]
  12. Kremsner PG, Krishna S, , 2004. Antimalarial combinations. Lancet 364: 285294.[Crossref]
  13. Fernandez FM, Hostetler D, Powell K, Kaur H, Green MD, Mildenhall DC, Newton PN, , 2011. Poor quality drugs: grand challenges in high throughput detection, countrywide sampling, and forensics in developing countries. Analyst 136: 30733082.[Crossref]
  14. Kaur H, Green MD, Hostetler DM, Fernández FM, Newton PN, , 2010. Antimalarial drug quality: methods to detect suspect drugs. Therapy 7: 4957.[Crossref]
  15. Blessy M, Patel RD, Prajapati PN, Agrawal YK, , 2014. Development of forced degradation and stability indicating studies of drugs: a review. J Pharm Anal 4: 159165.[Crossref]
  16. Acker KV, Mommaerts M, Vanermen S, Meskens J, Vander Heyden Y, Plaizier-Vercammen J, , 2012. Chemical stability of artemisinin derivatives. Malar J 11 (Suppl 1): P99.[Crossref]
  17. Batty KT, Ilett KF, Davis T, Davis ME, , 1996. Chemical stability of artesunate injection and proposal for its administration by intravenous infusion. J Pharm Pharmacol 48: 2226.[Crossref]
  18. World Health Organization, 2009. Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products. WHO Technical Report Series No. 953, Annex 2. Available at: http://apps.who.int/medicinedocs/en/d/Js19133en/. Accessed August 28, 2015.
  19. Kaur H, Allan EL, Mamadu I, Hall Z, Ibe O, El Sherbiny M, van Wyk A, Yeung S, Swamidoss I, Green MD, Dwivedi P, Culzoni MJ, Clarke S, Schellenberg D, Fernández FM, Onwujekwe O, , 2015. Quality of artemisinin-based combination formulations for malaria treatment: prevalence and risk factors for poor quality medicines in public facilities and private sector drug outlets in Enugu, Nigeria. PLoS One 10: e0125577.[Crossref]
  20. Jain D, Basniwal PK, , 2013. Forced degradation and impurity profiling: recent trends in analytical perspectives. J Pharm Biomed Anal 86: 1135.[Crossref]
  21. Hostetler DM, Dwivedi P, Green MD, Fernandez FM, , 2012. High throughput quantitation of artesunate and its degradation products by flow injection gradient ratio standard addition mass spectrometry (FI-GRSA-MS). Anal Methods 4: 33923398.[Crossref]
  22. Bajaj S, Singla D, Sakhuja N, , 2012. Stability testing of pharmaceutical products. J Appl Pharm Sci 2: 129138.
  23. Haynes RK, Chan H-W, Lung C-M, Ng N-C, Wong H-N, Shek LY, Williams ID, Cartwright A, Gomes MF, , 2007. Artesunate and dihydroartemisinin (DHA): unusual decomposition products formed under mild conditions and comments on the fitness of DHA as an antimalarial drug. Chem Med Chem 2: 14481463.[Crossref]
  24. van Schalkwyk DA, Burrow R, Henriques G, Gadalla NB, Beshir KB, Hasford C, Wright SG, Ding XC, Chiodini PL, Sutherland CJ, , 2013. Culture-adapted Plasmodium falciparum isolates from UK travellers: in vitro drug sensitivity, clonality and drug resistance markers. Malar J 12: 320334.[Crossref]
  25. World Health Organization. WHO List of Prequalified Medicinal Products. Available at: http://apps.who.int/prequal/query/ProductRegistry.aspx. Accessed August 28, 2015.
  26. Van Quekelberghe SAA, Soomro SA, Cordonnier JA, Jansen FH, , 2008. Optimization of an LC-MS method for the determination of artesunate and dihydroartemisinin plasma levels using liquid-liquid extraction. J Anal Toxicol 32: 133139.[Crossref]
  27. Vandercruyssen K, D'Hondt M, Vergote V, Jansen H, Burvenich C, De Spiegeleer B, , 2014. LC–UV/MS quality analytics of paediatric artemether formulations. J Pharm Anal 4: 3752.[Crossref]
  28. Verbeken M, Suleman S, Baert B, Vangheluwe E, Van Dorpe S, Burvenich C, Duchateau L, Jansen FH, De Spiegeleer B, , 2011. Stability-indicating HPLC-DAD/UV-ESI/MS impurity profiling of the anti-malarial drug lumefantrine. Malar J 10: 51.[Crossref]
  29. Wong RPM, Salman S, Ilett KF, Siba PM, Mueller I, Davis TME, , 2011. Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. Antimicrob Agents Chemother 55: 11941198.[Crossref]
  30. Suleman S, Vandercruyssen K, Wynendaele E, D'Hondt M, Bracke N, Duchateau L, Burvenich C, Peremans K, De Spiegeleer B, , 2013. A rapid stability-indicating, fused-core HPLC method for simultaneous determination of β-artemether and lumefantrine in anti-malarial fixed dose combination products. Malar J 12: 145.[Crossref]
  31. Jansen F, , 2010. The pharmaceutical death-ride of dihydroartemisinin. Malar J 9: 212.[Crossref]
  32. Kauss T, Fawaz F, Guyot M, Lagueny A-M, Dos Santos I, Bonini F, Olliaro P, Caminiti A, Millet P, , 2010. Fixed artesunate–amodiaquine combined pre-formulation study for the treatment of malaria. Int J Pharm 395: 198204.[Crossref]
  33. Lacaze C, Kauss T, Kiechel J-R, Caminiti A, Fawaz F, Terrassin L, Cuart S, Grislain L, Navaratnam V, Ghezzoul B, Gaudin K, White NJ, Olliaro PL, Millet P, , 2011. The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership. Malar J 10: 142.[Crossref]
  34. Bate R, Tren R, Hess K, Attaran A, , 2009. Physical and chemical stability of expired fixed dose combination artemether-lumefantrine in uncontrolled tropical conditions. Malar J 8: 33.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.15-0665
Loading
/content/journals/10.4269/ajtmh.15-0665
Loading

Data & Media loading...

Supplementary Data

Supplementary PDF

  • Received : 11 Sep 2015
  • Accepted : 13 Jan 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error